Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) [Phase 2]

View source ↗

Summary

This document provides a status update on a Phase 2 clinical trial evaluating belantamab mafodotin in combination with standard of care for relapsed-refractory …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Belantamab Mafodotin (belantamab mafodotin)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma | Phase 2 | Status: NOT_YET_RECRUITING